Clinical Trial: A Single-Center, Single-Arm, Phase II Window-of-Opportunity Clinical Study of Dalpiciclib Combined with Endocrine Therapy in HR+/HER2- Breast Cancer after Neoadjuvant Chemotherapy（ Lumen） (China)

China, Nov. 2 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'A Single-Center, Single-Arm, Phase II Window-of-Opportunity Clinical Study of Dalpiciclib Combined with Endocrine Therapy in HR+/HER2- Breast Cancer after Neoadjuvant Chemotherapy（ Lumen）'. The following are the other relevant details related to the trial:

Registration Number: ChiCTR2600135680

Registration Time: 2026/11/01

Type: Interventional study

Primary Sponsor: Huizhou Central People's Hospital

To know more, click on https://www.chictr.org.cn/showprojEN.html?proj=343864

Published by HT Digital Content Services with permission from Health Daily Digest....